Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Eritoran is a synthetic lipid that inhibits the receptor TLR4. It was developed as a potential treatment for severe sepsis, an excessive inflammatory response to an infection. It failed a five year Phase III clinical trial, the results of which were published in 2013, and as of 2014 was no longer being developed.
Companies & Overview
Explore the main themes, entities and connections around Eritoran. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
tlr4 developed part lipid inhibits sepsis triggering defense binds salt tetrasodium receptor infection sodium pathogens synthetic potential treatment severe excessive
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Eritoran | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Eritoran | ATC code | none | 1.00 | infobox |
| Eritoran | CAS Number | 185955-34-4 N 185954-98-7 (tetrasodium salt) | 1.00 | infobox |
| Eritoran | ChEMBL | ChEMBL501259 N | 1.00 | infobox |
| Eritoran | ChemSpider | 5288721 N | 1.00 | infobox |
| Eritoran | CompTox Dashboard (EPA) | DTXSID60873217 | 1.00 | infobox |
| Eritoran | DrugBank | DB04933 N | 1.00 | infobox |
| Eritoran | Formula | C66H126N2O19P2 | 1.00 | infobox |
| Eritoran | IUPHAR/BPS | 4919 | 1.00 | infobox |
| Eritoran | KEGG | DG01426 N | 1.00 | infobox |
| Eritoran | Molar mass | 1313.677 g·mol−1 | 1.00 | infobox |
| Eritoran | Other names | E 5564 | 1.00 | infobox |
| Eritoran | PubChem CID | 6912404 | 1.00 | infobox |
| Eritoran | Routes of administration | Intravenous injection | 1.00 | infobox |
| Eritoran | UNII | 551541VI0Y | 1.00 | infobox |
| Eritoran | is a | synthetic lipid that inhibits the receptor TLR4 | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.